News & Events about Terns Pharmaceuticals Inc.
Terns Pharmaceuticals (NASDAQ:TERN Get Rating) had its target price increased by JPMorgan Chase & Co. from $6.00 to $9.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. Several other analysts have also recently commented on the stock. The ...
Ticker Report
5 months ago
Terns Pharmaceuticals (NASDAQ:TERN Get Rating) and Phibro Animal Health (NASDAQ:PAHC Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings...
Globe Newswire
6 months ago
Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in OncologyFOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
UBS Group assumed coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN Get Rating) in a research note published on Tuesday , Marketbeat.com reports. The brokerage issued a buy rating and a $19.00 target price on the stock. A number of other research analysts have also recently issued reports on ...
Globe Newswire
9 months ago
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic ...